FZRQ — Immune Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Annual income statement for Immune Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2013 December 31st | 2014 December 31st | 2015 December 31st | 2016 December 31st | 2017 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.019 | 0.002 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 2.58 | 16.4 | 16.2 | 27.3 | 16 |
| Operating Profit | -2.56 | -16.4 | -16.2 | -27.3 | -16 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -5.75 | -23.6 | -17.2 | -37.5 | -19.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -5.76 | -23.6 | -17.2 | -32.7 | -19.7 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -5.76 | -23.6 | -17.2 | -32.7 | -17.9 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -6.69 | -24.4 | -24.1 | -40.6 | -24.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -30.7 | -29.2 | -17.7 | -6.64 | -2.02 |